UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.35
Equity-to-Asset	0.58
Debt-to-Equity	0.34
Debt-to-EBITDA	2.38
Interest Coverage	4.91
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.21	Distress Grey Safe
Beneish M-Score	-2.45	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-0.8
	3-Year EBITDA Growth Rate	-0.8
	3-Year EPS without NRI Growth Rate	-25.4
	3-Year FCF Growth Rate	-15.4
	3-Year Book Growth Rate	7.1
	Future 3-5Y EPS without NRI Growth Rate	22.12
	Future 3-5Y Total Revenue Growth Rate	10.5

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	36.41
	9-Day RSI	49.23
	14-Day RSI	56.51
	6-1 Month Momentum %	65.63
	12-1 Month Momentum %	35.78

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.32
	Quick Ratio	0.92
	Cash Ratio	0.4
	Days Inventory	203.13
	Days Sales Outstanding	60.83
	Days Payable	225.51

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.12
	Dividend Payout Ratio	0.76
	3-Year Dividend Growth Rate	2.4
	Forward Dividend Yield %	1.12
	5-Year Yield-on-Cost %	1.26
	3-Year Average Share Buyback Ratio	-0.1
	Shareholder Yield %	1.25

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	67.5
	Operating Margin %	12.05
	Net Margin %	6.53
	FCF Margin %	8.47
	ROE %	3.8
	ROA %	2.2
	ROIC %	3.71
	ROC (Joel Greenblatt) %	38.59
	ROCE %	4.57
	Years of Profitability over Past 10-Year	10

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	68.44
	Forward PE Ratio	27.7
	PE Ratio without NRI	68.75
	Shiller PE Ratio	19.37
	Price-to-Owner-Earnings	45.76
	PS Ratio	4.48
	PB Ratio	2.55
	Price-to-Free-Cash-Flow	52.92
	Price-to-Operating-Cash-Flow	30.92
	EV-to-EBIT	42.46
	EV-to-Forward-EBIT	36.41
	EV-to-EBITDA	19.47
	EV-to-Forward-EBITDA	18.47
	EV-to-Revenue	4.73
	EV-to-Forward-Revenue	4.44
	EV-to-FCF	55.82
	Price-to-Projected-FCF	1.68
	Price-to-Median-PS-Value	2.44
	Earnings Yield (Greenblatt) %	2.36
	FCF Yield %	1.95
	Forward Rate of Return (Yacktman) %	-12.34

GF Value: €79.82

XBRU:UCB

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with UCB. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.